Literature DB >> 35840170

Authors' Reply: "On the Importance of Considering Glycosylation when Evaluating Biologic Therapies".

Andrea Angeletti1,2, Pietro Ravani3, Maurizio Bruschi2, Gian Marco Ghiggeri4,2.   

Abstract

Entities:  

Keywords:  anti-CD20 antibodies; focal segmental glomerulosclerosis; glomerulonephritis; idiopathic nephrotic syndrome; membranous nephropathy; obinutuzumab; pediatric nephrology; rituximab; vasculitis

Mesh：

Substances：

Year:  2022        PMID： 35840170      PMCID： PMC9342639          DOI： 10.1681/ASN.2022050534

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


× No keyword cloud information.
  4 in total

1.  Colloquium paper: uniquely human evolution of sialic acid genetics and biology.

Authors:  Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

2.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Authors:  Pietro Ravani; Alberto Magnasco; Alberto Edefonti; Luisa Murer; Rossella Rossi; Luciana Ghio; Elisa Benetti; Floriana Scozzola; Andrea Pasini; Nadia Dallera; Felice Sica; Mirco Belingheri; Francesco Scolari; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

3.  A red meat-derived glycan promotes inflammation and cancer progression.

Authors:  Annie N Samraj; Oliver M T Pearce; Heinz Läubli; Alyssa N Crittenden; Anne K Bergfeld; Kalyan Banda; Christopher J Gregg; Andrea E Bingman; Patrick Secrest; Sandra L Diaz; Nissi M Varki; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

4.  Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.

Authors:  Pietro Ravani; Manuela Colucci; Maurizio Bruschi; Marina Vivarelli; Michela Cioni; Armando DiDonato; Paolo Cravedi; Francesca Lugani; Francesca Antonini; Marco Prunotto; Francesco Emma; Andrea Angeletti; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2021-09-20       Impact factor: 14.978
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.